Sarepta Therapeutics Announces Promising Results From Clinical Trial Of Gene Therapy For Limb-Girdle Muscular Dystrophy.
February 28, 2019
STAT (2/27, Feuerstein) reports Sarepta Therapeutics announced early results from a clinical trial of MYO-101, a gene therapy for limb-girdle muscular dystrophy. The company said that three patients with limb-girdle muscular dystrophy received an infusion...